Semper Paratus Acquisition and Tevogen Bio today announced that the registration statement outlining the deal has een declared effective by the SEC.
A meeting date for Semper Paratus shareholders to vote on the deal has not been set. The SPAC’s completion date is not until September.
Redemptions ahead of the successful extension vote last month left $16.5 million cash in trust.
Tevogen is a clinical-stage specialty immunotherapy biotech company developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
When announced in June, the deal had a pro forma equity value of approximately $1.2 billion.
Sempter Paratus raised $345 million in a November 2021 IPO. The SPAC in May sold its sponsor equity to SSVK Associates. Read more.
